Short Review of Liposteroid

Biplab K. Saha, Nils T. Milman

Short Review of Liposteroid

Číslo: 4/2021
Periodikum: Prague Medical Report
DOI: 10.14712/23362936.2021.23

Klíčová slova: Liposteroid, Dexamethasone, Liposome, Idiopathic pulmonary hemosiderosis, Autoimmune disease, COVID-19

Pro získání musíte mít účet v Citace PRO.

Přečíst po přihlášení

Anotace: This paper briefly reviews the safety and efficacy of liposteroid in different inflammatory and non-inflammatory diseases. Corticosteroids (CS) are the first-line therapy in many inflammatory and autoimmune disorders. Although highly efficacious, long-term use of CS is limited due to the occurrence of significant side effects. Liposteroid, which is a liposomal formulation of dexamethasone palmitate, possess more potent anti-inflammatory and immunosuppressive properties compared to dexamethasone sodium phosphate. These two formulations have markedly different lipid solubility, resulting in different pharmacokinetic and pharmacodynamic properties. Liposteroid has been used with success in patients with rheumatoid arthritis, macrophage activation syndrome, and idiopathic pulmonary hemosiderosis. In addition, liposteroid has been used in some non-inflammatory diseases. Moreover, we conceive that liposteroid may have a beneficial effect in patients, who are critically ill due to COVID-19, and suffer from the macrophage activation syndrome.